IN-B00009

Phase 3Small molecule

HHK inno.N Corporation

IN-B00009 is one of 93 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyNot yet recruiting

Diabetes MellitusNot yet recruiting

Efficacy and SafetyPhase 3

Not yet recruiting

Diabetes MellitusPhase 3

Not yet recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

4 2

Savaysa

Daiichi Sankyo

Phase 3

3 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 4

Rapamune

PPrism Pharmaceuticals

Phase 3

5 5

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 6

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 9

Becotatug Vedotin

FFudan University

Phase 3

1 10

Raphamin

MMateria Medica Holding

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Efficacy and Safety

NCT07308184

Phase 3Not yet recruiting

Diabetes Mellitus

NCT07192263

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus

Not yet recruiting·HHK inno.N Corporation·Phase 3·NCT07192263·300 enrolled

Efficacy and Safety1 trial

Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

Not yet recruiting·HHK inno.N Corporation·Phase 3·NCT07308184·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IN-B00009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IN-B00009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IN-B00009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HK inno.N Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHK inno.N Corporation

IN-B00009

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Diabetes Mellitus1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News